Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2Small Cell Lung Carcinoma 1Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Ovarian Neoplasms 1MET Positive 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 4Leucovorin 4Irinotecan 4Fluorouracil 4Capecitabine 3Bevacizumab 3cobimetinib 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Standard of Care 2Specimen Handling 2Panitumumab 2Magnetic Resonance Spectroscopy 2Ketamine 2Hydroxychloroquine 2Cyclophosphamide 2Cisplatin 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1sodium thiosulfate 1rucaparib 1romiplostim 1rilotumumab 1regorafenib 1pralsetinib 1ponatinib 1pembrolizumab 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Neoplasms × rilotumumab × Clear all
NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NantBioScience, Inc.

Phase 1/2 Completed
177 enrolled 31 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡